MAPK14 and prostate carcinoma: Moreover, cisplatin (Cis) and carboplatin (Carbo) were reported to activate all three MAPKs, whereas docetaxel (Doce) and cabazitaxel (Caba) activated p38 and JNK1/2 while inhibiting ERK1/2 in prostate cancer cells44.